LENZ THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $19.1M | $0 |
| Cost of Revenue | $418.0K | $0 |
| Gross Profit | $18.7M | $0 |
| Gross Margin | 97.8% | — |
| Operating Expenses | ||
| Research & Development | $18.7M | $29.8M |
| SG&A Expense | $91.1M | $28.8M |
| Operating Income | $-91.1M | $-58.6M |
| Operating Margin | -477.5% | — |
| Interest Expense | — | — |
| Pretax Income | $-81.6M | $-49.8M |
| Income Tax Expense | $502.0K | $1.0K |
| Net Income | $-82.1M | $-49.8M |
| Net Margin | -430.3% | — |
| EPS (Basic) | $-2.85 | $-2.34 |
| EPS (Diluted) | $-2.85 | $-2.34 |
| Shares Outstanding (Basic) | 28.8M | 21.3M |
| Shares Outstanding (Diluted) | 28.8M | 21.3M |
| Dividends Per Share | — | — |